6-amino-2-[2-[[6-(2,4-dichlorophenyl)-5-(4-methylsulfonyl-2-oxopiperazin-1-yl)pyridin-2-yl]amino]ethylamino]-N-hydroxy-2H-pyridin-5-imine oxide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-amino-2-[2-[[6-(2,4-dichlorophenyl)-5-(4-methylsulfonyl-2-oxopiperazin-1-yl)pyridin-2-yl]amino]ethylamino]-N-hydroxy-2H-pyridin-5-imine oxide
• 化学式: C23H26Cl2N8O5S
• 分子量: 597.5
• InChiKey: FZEQMUDOEZEVDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  190
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3
  申请人：CHIRON CORPORATION

  公开号：EP1317433A2

  公开（公告）日：2003-06-11
• [EN] INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3<br/>[FR] INHIBITEURS DE GLYCOGENE-SYNTHASE KINASE 3
  申请人：CHIRON CORP

  公开号：WO2002020495A2

  公开（公告）日：2002-03-14

  New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.